Key facts
- BioHarv’s last known valuation is $1.9M (Oct 2025).
- It has raised $340K; the latest was Seed Round ($340K) in Oct 2025.
- Notable investors include Zinc, ICURe.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioHarv
- ·The full record, as it builds
Funding rounds
No funding rounds for BioHarv are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioHarv
Developer of implantable monitoring technology designed for long-term physiological assessment. The company's platform uses battery-free implantable hardware and continuous data-capture mechanisms to support uninterrupted cardiac monitoring, enabling healthcare providers to track patient cardiac activity over extended periods without repeated invasive battery replacements or frequent maintenance demands.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- bio-harv.replit.app/
- Ownership
- Privately Held (backing)
BioHarv doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioHarv shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioHarv in its N-PORT filings yet. We sweep new filings monthly.